#161899

TOV3133D

Cat. #161899

TOV3133D

Cat. #: 161899

Organism: Human

Tissue: Ovary

Disease: Cancer

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Létourneau, et al. 2012. BMC Cancer. 29,12:379. PMID: 22931248

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: TOV3133D
  • Organism: Human
  • Tissue: Ovary
  • Donor: Donor was age 52 ay time of diagnosis with Stage 3 IIIC ovarian serous papillary adenocarcinoma. Patient had a TP53 mutation at Exon 6. Specimen collection took place in 2006. Patient underwent treatment of paclitaxel and carboplatin 1-3 months after surgery and confirmation of the ovarian cancer diagnosis. A second surgery was performed 6 months after the first which showed infiltration of tumor in many areas of the abdomen. After this, patient was put on doxorubicin for 5 months and carboplatin and gemcitabine 13 months afer diagnosis for a total of 6 months. Patient did not show a clear response to chemotherapy with evidence of progressive disease after 5 months.
  • Disease: Cancer
  • Morphology: Was able to form semi-compact spheroids
  • Growth properties: Mixed
  • Crispr: No
  • Description: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer taken pre-chemotherapy from primary disease. This cell line also formed tumors at subcutaneous sites in SCID mice. Three other cell lines from this patient are available and take at different distinct time points throughout treatment offering possible insights into the mechanisms of tumor progression and evolution.
  • Production details: Solid ovarian tumor derived cell line was established using the scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days. Medium was replaced weekly.
  • Biosafety level: 1

Handling

  • Format: Frozen
  • Growth medium: OSE medium, 10% FBS, 0.5ug/ml apmphotericin B and 50ug/ml gentamycin sulfate
  • Temperature: 37° C
  • Atmosphere: 5% O2 and 5% CO2
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen
  • Cultured in antibiotics: 2.5ug/ml amphotericin B and 50 ug/ml gentamicin
  • Str profiling: TH01: 7,9.3 / D21S11: 30,32.2 / D5S818: 12 / D13S317: 13 / D7S820: 8,12 / D16S539: 13 / CSF1PO: 11,12 / vWA: 17 / TPOX: 8,11 / AMEL: X

References

  • Asare-Werehene, et al. 2023. Cancers (Basel). 30,15(9):2566. PMID: 37174032
  • Vias, et al. 2023. Elife. 11,12:e83867. PMID: 37166279
  • Tomas, et al. 2023. J Ovarian Res. 11, 16(1):70. PMID: 37038202
  • Létourneau, et al. 2012. BMC Cancer. 29,12:379. PMID: 22931248